Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

• Main Authors: Yuan Chen (Author), Fang Ma (Author), Nicholas S. Jones (Author), Kenta Yoshida (Author), Po‐Chang Chiang (Author), Matthew R. Durk (Author), Matthew R. Wright (Author), Jin Yan Jin (Author), Leslie W. Chinn (Author)
• Format: Book
• Published: Wiley, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fenebrutinib is a CYP3A substrate and time‐dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically‐based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug‐drug interactions (DDIs) and proposing doses for untested...